SIDE-BY-SIDE REFERENCE
Semaglutide, MOTS-c, and NAD+: How They Compare
Three different entry points into metabolic and cellular-aging research — compared by class, mechanism, evidence maturity, and regulatory status.
The short version
Semaglutide, MOTS-c, and NAD+ are studied in overlapping metabolic and aging contexts but represent three distinct types of compound with very different evidence bases. Semaglutide is an FDA-approved prescription medicine with large randomized trials. MOTS-c is a mitochondrial-derived research peptide with no human efficacy trials. NAD+ is an endogenous coenzyme marketed as a supplement, with human evidence primarily at the biomarker level rather than clinical endpoints. The table below sets them side by side on the dimensions that matter most for reading the literature.
Comparison table
| Dimension | Semaglutide | MOTS-c | NAD+ |
|---|---|---|---|
| Class | GLP-1 receptor agonist peptide (incretin mimetic) | Mitochondrial-derived peptide (MDP) | Endogenous redox coenzyme / dietary supplement |
| Origin | Synthetic analogue of human GLP-1 (31 AA; ~94% homology) | Encoded by mitochondrial DNA (12S rRNA gene; 16 AA) | Endogenous dinucleotide; synthesized from precursors (tryptophan, NMN, NR, NA) |
| Primary target | GLP-1 receptor (pancreas, hypothalamus, brainstem, cardiovascular/renal) | AMPK via folate-cycle inhibition; direct binding of CK2 in skeletal muscle; NRF2/ARE in nucleus under stress | Sirtuins (SIRT1-7), PARPs (PARP1), CD38; mitochondrial redox couple |
| What it is studied for | T2D glycemia; weight management; CV-risk reduction; kidney protection; MASH | Insulin sensitivity; metabolic homeostasis; age-related physical decline; exercise-mimetic effects | Energy metabolism; DNA repair; cellular aging; insulin sensitivity (via precursors NMN/NR) |
| Evidence maturity (human) | Phase 3 RCTs with tens of thousands of participants; multiple approved indications | Observational biomarker data only (n=94, hemodialysis cohort) [7]; no human efficacy trials | Precursor-driven blood NAD+ elevation well documented in RCTs [14][17]; clinical endpoint translation limited per 2025 review [13] |
| Key human finding | STEP 1: −14.9% body weight vs −2.4% placebo [4]; SELECT: HR 0.80 for MACE [3]; FLOW: HR 0.76 for kidney composite [2] | MOTS-c independently associated with mortality/CV composite in 94-person hemodialysis cohort (Cox HR 1.004) [7] | NMN at 250 mg/day improved muscle insulin sensitivity in prediabetic women [15]; NR dose-dependently raised blood NAD+ 22–142% [17] |
| Regulatory status (FDA) | Approved (T2D, weight management, CV outcomes, MASH) | Not approved; sold as research chemical for laboratory use | Not a drug; sold as dietary supplement; NMN supplement status contested by FDA |
| WADA status | Not prohibited; not on prohibited list as of corpus revision | Prohibited (peptide/metabolic-modulator category); athlete use can result in sanctions | Not prohibited (NAD+, NMN, NR, nicotinamide) |
| Key safety note | GI intolerance (nausea 1-in-3 patients); boxed warning for MTC history; biliary disease increased; weight regain on stopping [5] | No human safety data from trials; research-chemical quality variation; anti-doping prohibition | IV infusion endotoxin recall (compounded product); theoretical oncology concern; NMN regulatory uncertainty |
How they connect
The three compounds in this desk share a metabolic-and-aging research context even though they approach it from entirely different angles.
Semaglutide targets extracellular metabolic signaling — the GLP-1 receptor cascade that governs glucose disposal, appetite, and cardiovascular risk from outside the cell. Its mechanism is well understood and pharmacologically engineered for duration and potency [4].
MOTS-c emerges from intracellular metabolic stress sensing — the mitochondria themselves appear to release it as a signal when energy balance is challenged, and it feeds into AMPK, the same low-fuel alarm that sits downstream of exercise and caloric restriction [11]. The connection to NAD+ is direct: AMPK activation increases NAD+ availability by promoting NAMPT expression and mitochondrial biogenesis.
NAD+ is the biochemical substrate that underlies much of what both the other compounds modulate. Sirtuin activation — which requires NAD+ — is downstream of AMPK. The DNA-repair enzymes whose activity declines with NAD+ are the same ones that protect against the genomic instability associated with cellular aging.
They do not study the same mechanisms, and they do not have equivalent evidence. But they do illuminate the same set of questions about what goes wrong in metabolic aging — from three different levels of the biology.